Correlates of Adverse Events During Saphenous Vein Graft Intervention With Distal Embolic Protection A PRIDE Substudy

被引:12
|
作者
Kirtane, Ajay J. [2 ]
Heyman, Eugene R.
Metzger, Christopher [3 ]
Breall, Jeffrey A. [4 ]
Carrozza, Joseph P., Jr. [1 ]
机构
[1] Harvard Univ, Beth Israel Deaconess Med Ctr, Sect Intervent Cardiol, Sch Med,Dept Med, Boston, MA 02215 USA
[2] Columbia Univ, Med Ctr, Ctr Intervent Vasc Therapy, New York, NY USA
[3] Ctr Heart, Kingsport, TN USA
[4] Indiana Univ Med, Krannert Inst Cardiol, Indianapolis, IN USA
关键词
D O I
10.1016/j.jcin.2008.01.002
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives We sought to identify correlates of 30-day adverse events among patients undergoing percutaneous coronary intervention (PCI) of saphenous vein grafts (SVG). Background Although the use of distal embolic protection devices during SVG intervention reduces major adverse cardiac events (MACE), many patients still experience MACE despite distal embolic protection, and the major predictors of MACE among these patients are not well-characterized. Methods Correlates of 30-day MACE and pen-procedural creatine kinase-myocardial band (CK-MB) elevation were assessed among 631 patients undergoing SVG intervention with distal embolic protection enrolled in the PRIDE (PRotection during saphenous vein graft Intervention to prevent Distal Embolization) study, a randomized comparison of the TriActiv System (Kensey-Nash Corp., Exton, Pennsylvania) with an active control group (Guardwire [Medtronic, Santa Clara, California] or Filter-wire [Boston Scientific, Minneapolis, Minnesota]). Results Baseline covariates associated with MACE were longer lesion length, greater angiographically assessed estimated plaque volume, and higher SVG degeneration score. Graft age and angina class were not associated with adverse events. Angiographic lesion length was significantly correlated with more complex angiographic metrics such as estimated plaque volume and the SVG degeneration score. In multivariable analyses, angiographic lesion length was the strongest independent correlate of MACE (odds ratio [OR] 2.81 [95% confidence interval (CI) 1.82 to 4.34]log-increase in lesion length, p < 0.001) with a graded increase in MACE observed with increasing lesion lengths. Similarly, the strongest independent correlate of CK-MB elevation was lesion length (OR 2.54 [95% CI 1.59 to 4.04]/log-increase in lesion length, p < 0.001). The associations between lesion length and both MACE and CK-MB elevation were consistent among the studied embolic protection devices (TriActiv, Guardwire, or Filterwire). Conclusions Angiographic lesion length was the strongest correlate of short-term adverse events among patients undergoing SVG intervention with distal embolic protection, with incremental effects noted at even relatively short lesion lengths. (J Am Coll Cardiol Intv 2008;1:186-91) (C) 2008 by the American College of Cardiology Foundation
引用
收藏
页码:186 / 191
页数:6
相关论文
共 50 条
  • [21] Successful treatment of a distal saphenous vein graft lesion using the ProxisTM embolic protection system
    Ambrose, Jay
    REVIEWS IN CARDIOVASCULAR MEDICINE, 2007, 8 (03) : 182 - 184
  • [22] Severity of thrombus score predicts adverse events after slanting in saphenous vein grafts with distal embolic protection: The FIRE trial
    Weisz, G
    Rogers, C
    Hermiller, J
    Feldman, R
    Hall, P
    Haber, R
    Masud, Z
    Cox, D
    Cambier, P
    Caputo, R
    Turco, M
    Mehran, R
    Popma, J
    Stone, GW
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 45 (03) : 85A - 85A
  • [23] Limitations of Embolic Protection in Saphenous Vein Graft Intervention: Insights from 202 Consecutive Patients
    Matar, Fadi A.
    Smith, Karen
    Rossi, Peter
    Vandormael, Michel
    Sullebarger, John. T.
    Taylor, Marc
    Caruncho, Charmaine
    Ali, Tarik
    Kerensky, Rick
    JOURNAL OF INTERVENTIONAL CARDIOLOGY, 2009, 22 (03) : 240 - 246
  • [24] Cost analysis of embolic complications and distal embolic protection devices for percutaneous coronary intervention in saphenous vein grafts.
    Senter, S
    Nathan, S
    Gupta, A
    Calvin, J
    Klein, L
    JOURNAL OF INVESTIGATIVE MEDICINE, 2004, 52 (02) : S379 - S379
  • [25] Does the beneficial effect of distal protection in saphenous vein graft interventions vary with lesion length? A SAFER (saphenous vein graft angioplasty free of emboli randomized) substudy
    Giugliano, GR
    Prpic, R
    Cutlip, DE
    Popma, JJ
    Ho, KL
    Mauri, L
    Kaya, U
    Wahr, D
    George, B
    Baim, DS
    Kuntz, RE
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 39 (05) : 9A - 9A
  • [26] Clinical and economic outcomes of distal embolic protection strategies for percutaneous coronary intervention in saphenous vein grafts
    Senter, SR
    Nathan, S
    Gupta, A
    Calvin, JE
    Klein, LW
    CIRCULATION, 2004, 110 (17) : 490 - 490
  • [27] Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts
    Leborgne, L
    Cheneau, E
    Waksman, R
    CIRCULATION, 2002, 106 (15) : E68 - E68
  • [28] Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts
    Baim, DS
    Wahr, D
    George, B
    Leon, MB
    Greenberg, J
    Cutlip, DE
    Kaya, U
    Popma, JJ
    Ho, KKL
    Kuntz, RE
    CIRCULATION, 2002, 105 (11) : 1285 - 1290
  • [29] Rebuttal: Innovative Embolic Protection Strategies for Saphenous Vein Graft Interventions
    Badhey, Neeraj
    Banerjee, Subhash
    Brilakis, Emmanouil S.
    CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2011, 77 (04) : 595 - 595
  • [30] Saphenous Vein Graft Recanalization Without Embolic Protection: Impossible is Nothing
    Belardi, Jorge A.
    Albertal, Mariano
    CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2011, 78 (01) : 70 - 71